The most complete! 11 cities issued 4 + 7 Rules for centralized mining, and 8 pilot areas "unsuccessful products" price adjustment policy summary

According to the official account of drug consistency evaluation, a few days ago, the Sichuan Medical Security Bureau issued a notice on organizing the centralized procurement and use of drugs in the state organization, and the central medicines selected from the state organization for centralized purchase of drugs were directly linked to the selected prices All the non selected medicines were not higher than those of the highest priced drugs in Shanghai The documents put forward the following requirements for the network connection of the selected drugs and non selected drugs: 1 The selected drugs are directly connected to the network according to the price of the selected drugs purchased by the state organization Among them, for the products not online in our province, relevant pharmaceutical enterprises shall supplement materials according to the requirements and improve the basic information of drug online 2、 Non selected drugs shall be arranged according to the national drug centralized procurement and use pilot work deployment meeting, and the non selected drugs involved in the pilot varieties shall maintain price linkage with the gradient price reduction results formed by joint procurement (or Shanghai) Non selective drug enterprises are encouraged to take the initiative to reduce prices and declare independently, so as to reach the same price According to the price comparison rule, the purchase "red line price" (hereinafter referred to as "red line price") in Chengdu is calculated as follows: all non selected drugs are not higher than the price reduction result of the highest price drugs in Shanghai Among them, the non selected drugs with different refined dosage forms, specifications and packages from the same manufacturer shall be adjusted according to the price difference ratio of the selected drugs; other non selected drugs that fail the consistency evaluation shall not be higher than the price of the selected drugs In addition, the province has made it clear that public medical institutions in non pilot areas will continue to implement the current policy of centralized drug procurement in Sichuan Province Up to now, 11 cities participating in the 4 + 7 centralized belt purchase have issued and implemented the bid winning products, and 8 pilot areas (Shanghai, Beijing, Liaoning, Tianjin, Guangzhou, Chongqing, Shenzhen, Sichuan) have issued the price adjustment policy for non bid winning varieties On the one hand, 11 cities maintain consistency in the implementation of procurement work for selected drugs, which is started in March, only with slightly different supporting policies, such as collection time, final prepayment of medical insurance fund, how to ensure the dosage of clinical use, etc On the other hand, what makes the whole industry pay more attention to is the establishment of online purchasing requirements and medical insurance payment standards for the non selected varieties in 11 cities Next, in addition to the above notice issued by Sichuan Province, see the detailed rules for the adjustment of the medical insurance payment standard for non selected drugs in other 7 pilot areas Chongqing: linked with 4 + 7 unselected drugs and other national minimum prices of generic names, on March 12, Chongqing drug exchange issued the notice on matters related to price adjustment of unselected drugs in centralized procurement organized by the state, which pointed out that: For the unselected drugs within the scope of joint purchase and price negotiation, if the result of joint purchase and price negotiation is lower than the current online price in Chongqing, the market price shall be adjusted according to the result of joint purchase and price negotiation, involving 156 articles and 37 drugs of 72 production enterprises The prices of other drugs under the same general name outside the scope of joint purchase and price negotiation shall be adjusted in accordance with the lowest price in the country Guangzhou: in the consultation, on March 11, Guangzhou Medical Insurance Bureau issued the notice on defining the payment standard of medical insurance for centralized purchase of drugs by national organizations (Draft for consultation), which clarified the relevant matters of the payment standard of medical insurance for centralized purchase of national pilot The implementation date of Guangzhou is delayed compared with other pilot areas, and it will be implemented from April 1, with a validity period of one year It is pointed out in the document that if the price of the non selected drugs purchased by the state at the end of 2018 is more than twice the price of the selected drugs, 70% of the price at the end of 2018 shall be taken as the payment standard of medical insurance (the payment standard of medical insurance for drugs of different specifications shall be calculated separately, the same below); if the price of the non selected drugs purchased by the state at the end of 2018 is less than twice the price of the selected drugs and the price of the selected drugs, the price of the selected drugs shall be taken as the payment standard of medical insurance Accurate The price of non selected drugs purchased by the state at the end of 2018 is calculated according to the drug purchase price of Guangzhou region of Guangdong Drug Trading Center at the end of 2018 1 If the actual price of drugs purchased by the state is lower than the selected price, the actual price shall be taken as the payment standard of medical insurance 2 For generic drugs that fail to pass the consistency evaluation, the medical insurance payment standard shall not be higher than the price of selected drugs 3 The medical expenses exceeding the medical insurance payment standard shall be borne by the insured Shenzhen: on March 13, the highest price drugs of 4 + 7 not selected will be subject to gradient price reduction Shenzhen full drug website issued the supplementary document of 4 + 7 city drug centralized purchase in Shenzhen, in which the price negotiation for 4 + 7 not selected varieties of centralized purchase is as follows: 1 For the drugs that meet the qualification of 4 + 7 centralized purchase documents but fail to be selected, if the purchase catalogue of Shenzhen public hospital drug group has been concluded in 2016 (the same as the common name, the same dosage form, the same specification and the same manufacturer), price negotiation shall be conducted according to the following rules: 1.1 for the highest price drugs of the same variety and specifications that are not selected according to the requirements of 4 + 7 centralized purchase documents, the price after gradient price reduction in Shanghai shall be taken as the upper price limit of the variety; 1.2 in addition to the above 1.1, other unselected drugs that meet the application requirements of 4 + 7 centralized purchase documents, the price reduction of the medical institutions provided by the Shenzhen pharmaceutical group purchasing platform shall not be less than 25% of the price difference between the medical institutions provided by the group purchasing platform in 2018 and the prices of the selected drugs If the price of the medical institutions that have not selected the drugs is still higher than the terminal retail price that is being implemented by other provinces and cities in the country, the price shall be adjusted according to the minimum terminal retail price of the drugs 2 For the drugs that meet the application requirements of 4 + 7 centralized purchase documents but are not selected, if the purchase catalogue of Shenzhen public hospital drug group has not been completed in 2016, they will not be included in the purchase platform of Shenzhen drug group in principle If the price of non selected drugs for medical institutions is lower than that of selected drugs, it can be incorporated into the procurement platform of Shenzhen pharmaceutical group only after it is reviewed and approved by experts organized by the competent department Liaoning: on March 8, 2014, the price adjustment independently declared by the non selected varieties enterprises was not as expected, and the Liaoning medicine and medical consumables purchase network released the notice on the implementation of the results of the selection of the 4 + 7 urban drug centralized purchase varieties and the results of the price reduction of the non selected drugs (hereinafter referred to as the notice) According to the notice, all public medical and health institutions in Shenyang and Dalian, including all provincial medical institutions in Shenyang and Dalian, and other public medical institutions with ownership, uniformly implemented the results of 4 + 7 urban drug centralized procurement varieties selection and the results of gradient price reduction of non selected varieties at 0:00 on March 20 Among them, 25 varieties were selected and 125 varieties were not selected Compared with the price reduction list in the notice, it is not difficult to find that most of the varieties that are not selected are original research drugs and reference preparations, and only a few of them fail to pass the consistency evaluation of generic drugs Most of the gradient price reduction results are higher than the winning results of the selected varieties According to the prediction of the industry, even if the price of the non selected varieties is reduced, but before the agreed purchase volume is completed, the procurement of the pilot public hospitals will basically be the national volume procurement of the selected varieties and the original research drugs Tianjin: the medical insurance Department of varieties that have not completed the price reduction application will not recognize the payment standard Tianjin is still carrying out the price adjustment of varieties that have not been selected On March 8, Tianjin Municipality issued the notice on the price adjustment of non selected varieties in the centralized purchase of 4 + 7 urban drugs, and the price adjustment of non selected varieties was carried out from March 9 The scope of adjustment includes: the centralized purchase of 4 + 7 urban drugs included in the payment scope of Tianjin medical insurance fails to select the same generic name (including dosage form); the centralized purchase of 4 + 7 urban drugs included in the Tianjin medical purchase platform fails to select the same generic name (including dosage form) For the drugs included in the adjustment scope, the relevant enterprises shall reduce the maximum supply price of our city in the form of independent application according to the following rules: (1) the drugs that have completed the gradient price reduction in Shanghai, The price of drugs with the same generic name (including dosage forms) that meet the requirements of 4 + 7 urban drug centralized purchase declaration shall not be higher than the price of drugs with the same generic name that have completed gradient price reduction in Shanghai (packaging and specifications shall conform to the price comparison rules); （3） Other generic drugs with the same generic name (including dosage forms) shall not be higher than the price of drugs with the same generic name (dosage forms, specifications and packaging shall conform to the price difference rules) selected in the centralized procurement of drugs in 4 + 7 cities Beijing: the price adjustment rules for unselected drugs to be adjusted Beijing's price adjustment for 4 + 7 unselected drugs is relatively strong On March 11, Beijing announced the requirements for setting reference prices for 4 + 7 unselected drugs, which are divided into two situations: First, it belongs to the original research drug and reference drug that are not selected under the same product name and generic drugs that pass the consistency evaluation of quality and efficacy Based on the price of non selected drugs negotiated in Shanghai as the standard, the price converted by differential price comparison is compared with the current national lowest price, and the lowest price is taken as the reference price for negotiation in Beijing The second is that the selected drugs belong to non original research drugs, non reference preparations and generic drugs that fail to pass the consistency evaluation of quality and efficacy under the same product name The price of the selected drugs is taken as the standard, and the price converted by differential price comparison is compared with the current national lowest price, and the lowest price is taken as the reference price for negotiation in Beijing Beijing requires relevant enterprises to declare the "promised supply price" of their products The promised supply price declared by enterprises shall not be higher than the reference price Medical institutions can purchase directly or negotiate separately according to the promised supply price For products with undeclared or declared committed supply price of "0", Beijing requires manufacturers to conduct "one-to-one" negotiation and procurement with medical institutions at a price no higher than the reference price according to the original sunshine procurement process Shanghai: on March 5, Shanghai issued a notice to adjust the price of some high price agreement drugs of the city for centralized purchase of state-organized drugs, which will be implemented from March 20, 2019 Among them, the price of 4 + 7 selected varieties was adjusted The adjusted purchase price of 100mg imatema mesylate tablets of Jiangsu hausen was 623.82 yuan / box, and that of 250mg gefitinib tablets of AstraZeneca was 547 yuan / box At the same time, the price of products that are not selected in 4 + 7 centralized purchase will also be reduced For example, the price of imatinib mesylate capsule 100mg * 12 tablets and 60 Tablets of Zhengda Tianqing were adjusted to RMB 124.38/box and RMB 586.39/box respectively Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.